Routinely vaccinating adolescents against meningococcus: targeting transmission & disease

References

• Baccarini C, Ternouth A, Wieffer H, et al. The changing epidemiology of meningococcal disease in North America 1945–2010. Hum Vaccin Immunother. 2013;9:162–171.
   PubMed Web of Science ®Google Scholar
• European Center for Disease Prevention and Control. Surveillance Report. Surveillance of invasive bacterial diseases in Europe 2012. [cited 2015 Aug 10]. Available from: http://ecdc.europa.eu/en/publications/Publications/Surveillance%20of%20IBD%20in%20Europe%202012.pdf.
   Google Scholar
• Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2013;62:1–28.
   PubMed Web of Science ®Google Scholar
• Vyse A, Anonychuk A, Jäkel A, et al. The burden and impact of severe and long-term sequelae of meningococcal disease. Expert Rev Anti Infect Ther. 2013;11:597–604.
   PubMed Web of Science ®Google Scholar
• Jolley KA, Brehony C, Maiden MCJ. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev. 2007;31:89–96.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Ochnio J, Ho M, et al. Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America. Emerg Infect Dis. 2004;10:1812–1815.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60:578–585.
   PubMed Web of Science ®Google Scholar
• Campbell H, Saliba V, Borrow R, et al. Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015. Euro Surveill Bull. 2015;20(28):pii=21188.
   Google Scholar
• Bröker M, Emonet S, Fazio C, et al Meningococcal serogroup Y disease in Europe continuation of high importance in some European regions in 2013. Hum Vaccines Immunother. 2015 ;11(9):2281–2286.
   PubMed Web of Science ®Google Scholar
• De Lemos APS, Yara TY, Gorla MCO, et al. Clonal distribution of invasive Neisseria meningitidis serogroup C strains circulating from 1976 to 2005 in greater Sao Paulo, Brazil. J Clin Microbiol. 2007;45:1266–1273.
   PubMed Web of Science ®Google Scholar
• Sáfadi MA, Bettinger JA, Maturana GM, et al. Evolving meningococcal immunization strategies. Expert Rev Vaccines. 2015;14:505–517.
   PubMed Web of Science ®Google Scholar
• WHO. Africa risks large meningitis outbreak. [cited 2015 Aug 10]. Available from: http://www.who.int/mediacentre/news/releases/2015/meningitis-africa/en/.
   Google Scholar
• Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines. 2010;9:285–298.
   PubMed Web of Science ®Google Scholar
• Castelblanco RL, Lee M, Hasbun R. Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study. Lancet Infect Dis. 2014;14:813–819.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs). [cited 2015 Aug 10]. Available from: http://www.cdc.gov/abcs/reports-findings/surv-reports.html.
   Google Scholar
• De Wals P, Deceuninck G, Boulianne N, et al. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA. 2004;292:2491–2494.
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(Suppl 1):S58–67.
   PubMed Web of Science ®Google Scholar
• Larrauri A, Cano R, García M, et al. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine. 2005;23:4097–4100.
   PubMed Web of Science ®Google Scholar
• Health AGD of Australian Meningococcal Surveillance Programme annual report, 2013. [cited 2015 May 18]. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3804f.htm
   Google Scholar
• Jordens JZ, Williams JN, Jones GR, et al. Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students. Infect Immun. 2004;72:6503–6510.
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969;129:1327–1348.
   PubMed Web of Science ®Google Scholar
• Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol. 2004;53:821–832.
   PubMed Web of Science ®Google Scholar
• Beddek AJ, Li M-S, Kroll JS, et al. Evidence for capsule switching between carried and disease-causing Neisseria meningitidis strains. Infect Immun. 2009;77:2989–2994.
   PubMed Web of Science ®Google Scholar
• Lipsitch M, O’Hagan JJ. Patterns of antigenic diversity and the mechanisms that maintain them. J R Soc Interface. 2007;4:787–802.
   PubMed Web of Science ®Google Scholar
• Caugant DA, Maiden MCJ. Meningococcal carriage and disease: population biology and evolution. Vaccine. 2009;27(Suppl 2):B64–70.
   PubMed Web of Science ®Google Scholar
• Lemée L, Hong E, Etienne M, et al. Genetic diversity and levels of expression of factor H binding protein among carriage isolates of Neisseria meningitidis. PloS One. 2014;9:e107240.
   PubMed Web of Science ®Google Scholar
• Yazdankhah SP, Kriz P, Tzanakaki G, et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol. 2004;42:5146–5153.
   PubMed Web of Science ®Google Scholar
• Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:853–861.
   PubMed Web of Science ®Google Scholar
• Soriano-Gabarró M, Wolter J, Hogea C, et al. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region. Expert Rev Anti Infect Ther. 2011;9:761–774.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Greenwood BM. Meningococcal carriage in the African meningitis belt. Lancet Infect Dis. 2007;7:797–803.
   PubMed Web of Science ®Google Scholar
• African Meningococcal Carriage Consortium. The diversity of meningococcal carriage across the African meningitis belt and the impact of vaccination with a group A meningococcal conjugate vaccine. J Infect Dis. 2015;212(8):1298–1307.
   Web of Science ®Google Scholar
• Trotter CL, McVernon J, Ramsay ME, et al. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine. 2008;26:4434–4445.
   PubMed Web of Science ®Google Scholar
• Jordens JZ, Williams JN, Jones GR, et al. Detection of meningococcal carriage by culture and PCR of throat swabs and mouth gargles. J Clin Microbiol. 2002;40:75–79.
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Anis S, Htun-Myint L, et al. Meningococcal disease in the Middle East and North Africa: an important public health consideration that requires further attention. Int J Infect Dis. 2012;16:e574–82.
   PubMed Web of Science ®Google Scholar
• Vyse A, Wolter JM, Chen JN, et al Meningococcal disease in Asia: an under-recognized public health burden. Epidemiol Infect. 2011;139(7):697–985.
   Web of Science ®Google Scholar
• MacLennan J, Kafatos G, Neal K, et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis. 2006;12:950–957.
   PubMed Web of Science ®Google Scholar
• Harrison LH, Kreiner CJ, Shutt KA, et al. Risk factors for meningococcal disease in students in grades 9–12. Pediatr Infect Dis J. 2008;27:193–199.
   PubMed Web of Science ®Google Scholar
• Sáfadi MAP, Carvalhanas TRMP, Paula De Lemos A, et al. Carriage rate and effects of vaccination after outbreaks of serogroup C meningococcal disease, Brazil, 2010. Emerg Infect Dis. 2014;20:806–811.
   PubMed Web of Science ®Google Scholar
• Rushdy A, Ramsay M, Heath PT, et al. Infant Hib vaccination and herd immunity. J Pediatr. 1999;134:253–254.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease: United States, 1998–2003. MMWR Morb Mortal Wkly Rep. 2005;54:893–897.
   PubMedGoogle Scholar
• Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179–1186.
   PubMed Web of Science ®Google Scholar
• Barbour ML. Conjugate vaccines and the carriage of Haemophilus influenzae type b. Emerg Infect Dis. 1996;2:176–182.
   PubMed Web of Science ®Google Scholar
• Bogaert D, Van Belkum A, Sluijter M, et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet. 2004;363:1871–1872.
   PubMed Web of Science ®Google Scholar
• Kaaijk P, Van Der Ende A, Berbers G, et al. Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? Experience from the Netherlands. BMC Infect Dis. 2012;12:35.
   PubMed Web of Science ®Google Scholar
• Hellenbrand W, Elias J, Wichmann O, et al Epidemiology of invasive meningococcal disease in Germany, 2002–2010, and impact of vaccination with meningococcal C conjugate vaccine. J Infect. 2013;66:48–56.
   PubMed Web of Science ®Google Scholar
• Public Health England. Invasive meningococcal infections laboratory reports in England by capsular group, age group & calendar year, 2000–2014. [ cited 2015 Aug 13]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/432895/Table_9_Invasive_meningococcal_infections_lab_reports_England_by_capsular_group_age.pdf.
   Google Scholar
• Ramsay ME, Andrews N, Kaczmarski EB, et al. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet. 2001;357:195–196.
   PubMed Web of Science ®Google Scholar
• Garrido-Estepa M, León-Gómez I, Herruzo R, et al. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification. Vaccine. 2014;32:2604–2609.
   PubMed Web of Science ®Google Scholar
• Macneil JR, Cohn AC, Zell ER, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J. 2011;30:451–455.
   PubMed Web of Science ®Google Scholar
• Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet. 2014;383:40–47.
   PubMed Web of Science ®Google Scholar
• Jodar L, Cartwright K, Feavers IM. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biol J Int Assoc Biol Stand. 2000;28:193–197.
   Google Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10:780–786.
   PubMedGoogle Scholar
• Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011;86:521–539.
   PubMedGoogle Scholar
• Vu DM, Welsch JA, Zuno-Mitchell P, et al. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis. 2006;193:821–828.
   PubMed Web of Science ®Google Scholar
• Borja-Tabora C, Montalban C, Memish ZA, et al. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infect Dis. 2013;13:116.
   PubMed Web of Science ®Google Scholar
• Baxter R, Baine Y, Bianco V, et al. Antibody persistence and safety 3 years after a single dose of MenACWY-TT vaccine in healthy individuals aged 10–25 years. 31st Annual Meeting of the European Society for Infectious Diseases (ESPID). Milan, Italy; 2013.
   Google Scholar
• Baxter R, Baine Y, Kolhe D, et al. 5-year Antibody persistence and booster response to a meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults. IDWeek, Presented in the (Vaccines:meningococcal) poster session. 2014; Oct 7–12; Philadelphia, PA. Abstract: 1086.
   Google Scholar
• Stoof SP, Van Der Klis FRM, Van Rooijen DM, et al. Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age: an intervention study among Dutch teenagers. PloS One. 2014;9:e100651.
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Lebacq E, Poolman J, et al. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years. Vaccine. 2009;27:161–168.
   PubMed Web of Science ®Google Scholar
• Bermal N, Huang L-M, Dubey A, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin. 2011;7:239–247.
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Silfverdal S-A, Berglund J, et al. A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix(®) in subjects aged 11-17 years: an open, randomised, controlled trial. Vaccine. 2012;30:774–783.
   PubMed Web of Science ®Google Scholar
• Lupisan S, Limkittikul K, Sosa N, et al. Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years. Clin Vaccine Immunol CVI. 2013;20:1499–1507.
   PubMed Web of Science ®Google Scholar
• Baxter R, Baine Y, Ensor K, et al. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J. 2011;30:e41–8.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Baxter R, Reisinger K, et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis. 2009;49:e1–10.
   PubMed Web of Science ®Google Scholar
• Halperin SA, Baine Y, Domachowske JB, et al. Comparison of the safety and immunogenicity of a novel quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine and a marketed quadrivalent meningococcal ACWY-diphtheria toxoid conjugate vaccine in healthy individuals 10–25 years of age. J Pediatr Infect Dis Soc. 2014;3:33–42.
   PubMedGoogle Scholar
• Jackson LA, Jacobson RM, Reisinger KS, et al. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J. 2009;28:86–91.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O’Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. The Lancet. 2012;379:617–624.
   PubMed Web of Science ®Google Scholar
• Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12:597–607.
   PubMed Web of Science ®Google Scholar
• Maiden MCJ, Ibarz-Pavón AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197:737–743.
   PubMed Web of Science ®Google Scholar
• Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384:2123–2131.
   PubMed Web of Science ®Google Scholar
• Korzeniewski K, Skoczyńska A, Guzek A, et al. Effectiveness of immunoprophylaxis in suppressing carriage of Neisseria meningitidis in the military environment. Adv Exp Med Biol. 2015;836:19–28.
   PubMed Web of Science ®Google Scholar
• Kristiansen PA, Diomande F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis. 2013;56:354–363.
   PubMed Web of Science ®Google Scholar
• Joint Committee on Vaccination and Immunisation - Groups - GOV.UK. [ cited 2015 Oct 20]. Available from: https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation#minutes.
   Google Scholar
• European Center for Disease Prevention and Control. Vaccination Schedules. [ cited 2015 Jul 06]. Available at: http://ecdc.europa.eu/en/activities/surveillance/euvac/schedules/Pages/schedules.aspx.
   Google Scholar
• Public Health Agency of Canada. Canadian Immunization Guide. Part 4 Active Vaccines. Hepatitis B Vaccine. 2015 [ cited 2015 Feb 20]. Available from: http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-hepb-eng.php.
   Google Scholar
• Australian Government Department of Health and Ageing, National Health and Medical Research Council. The Australian Immunisation Handbook 10th Edition (updated June 2015). [ cited 2015 Aug 14]. Available from: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home.
   Google Scholar
• Pan American Health Organization. Immunization Schedule for Selected Vaccines: Latin American Countries. 2014; [ cited 2015 Feb 20]. Available from: http://www.google.com.au/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&ved=0CCcQFjAB&url=http%3A%2F%2Fwww.paho.org%2Fhq.%2Findex.php%3Foption%3Dcom_docman%26task%3Ddoc_download%26gid%3D27699%26Itemid%3D3482%26lang%3Des&ei=cKXmVLa6LZXh8AXI34HwDw&usg=AFQjCNEuZjlw0BYHd_8Hd1E2rixCWhgb7g&sig2=w94F8Uyo6ni-wlXTjnlZ5w&bvm=bv.86475890,d.dGc
   Google Scholar
• Zollinger WD, Mandrell RE. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun. 1983;40:257–264.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365–367.
   PubMed Web of Science ®Google Scholar
• Auckland C, Gray S, Borrow R, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006;194:1745–1752.
   PubMed Web of Science ®Google Scholar
• Elam-Evans LD, Yankey D, Jeyarajah J, et al National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years: United States, 2013. MMWR Morb Mortal Wkly Rep. 2014;63:625–633.
   PubMed Web of Science ®Google Scholar
• Capua T, Katz JA, Bocchini JA. Update on adolescent immunizations: elected review of US recommendations and literature. Curr Opin Pediatr. 2013;25:397–406.
   PubMed Web of Science ®Google Scholar
• Ishola DA, Borrow R, Findlow H, et al. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin Vaccine Immunol. 2012;19:1126–1130.
   PubMed Web of Science ®Google Scholar
• Meningococcal C conjugate vaccine: advice for healthcare practitioners - Publications - GOV.UK. [ cited 2015 Oct 20]. Available from: https://www.gov.uk/government/publications/meningococcal-c-conjugate-vaccine-advice-for-healthcare-practitioners.
   Google Scholar
• MacNeil JR, Rubin L, McNamara L, et al. Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013. MMWR Morb Mortal Wkly Rep. 2014;63:527–530.
   PubMed Web of Science ®Google Scholar
• McNamara LA, Shumate AM, Johnsen P, et al. First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics. 2015;135:798–804.
   PubMed Web of Science ®Google Scholar
• Scott RD, Meltzer MI, Erickson LJ, et al. Vaccinating first-year college students living in dormitories for meningococcal disease: an economic analysis. Am J Prev Med. 2002;23:98–105.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Schuchat A, Gorsky RD, et al. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. Am J Public Health. 1995;85:843–845.
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Goh KT, Barkham T, et al. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis. 2003;36:679–683.
   PubMed Web of Science ®Google Scholar
• Impfplan Österreich 2012. Evidenz-basierte Empfehlungen des Nationalen Impfgremiums. [ cited 2015 Jul 03]. Available from: www.ktn.gv.at/239110_DE-Impf-Impfplan_2012.
   Google Scholar
• Pérez-Breva L, Villanueva RJ, Villanueva-Oller J, et al. Optimizing strategies for meningococcal C disease vaccination in Valencia (Spain). BMC Infect Dis. 2014;14:280.
   PubMed Web of Science ®Google Scholar
• Hepkema H, Pouwels KB, Van Der Ende A, et al. Meningococcal serogroup A, C, W135 and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands. PloS One. 2013;8:e65036.
   PubMed Web of Science ®Google Scholar
• Christensen H, Trotter CL, Hickman M, et al. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014;349:g5725.
   PubMed Web of Science ®Google Scholar
• Ortega-Sanchez IR, Meltzer MI, Shepard C, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis. 2008;46:1–13.
   PubMed Web of Science ®Google Scholar
• Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, et al. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics. 2005;115:1220–1232.
   PubMed Web of Science ®Google Scholar
• De Wals P, Coudeville L, Trottier P, et al. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. Vaccine. 2007;25:5433–5440.
   PubMed Web of Science ®Google Scholar
• Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol CVI. 2010;17:840–847.
   PubMed Web of Science ®Google Scholar
• National Vaccine Advisory Committee. The promise and challenge of adolescent immunization. Am J Prev Med. 2008;35:152–157.
   PubMed Web of Science ®Google Scholar
• Ford CA, English A, Davenport AF, et al. Increasing adolescent vaccination: barriers and strategies in the context of policy, legal, and financial issues. J Adolesc Health. 2009;44:568–574.
   PubMed Web of Science ®Google Scholar
• Middleman AB, Rosenthal SL, Rickert VI, et al. Adolescent immunizations: a position paper of the Society for Adolescent Medicine. J Adolesc Health. 2006;38:321–327.
   PubMed Web of Science ®Google Scholar
• Vandermeulen C, Roelants M, Theeten H, et al. Vaccination coverage in 14-year-old adolescents: documentation, timeliness, and sociodemographic determinants. Pediatrics. 2008;121:e428–34.
   PubMed Web of Science ®Google Scholar
• Kempe A, Barrow J, Stokley S, et al. Effectiveness and cost of immunization recall at school-based health centers. Pediatrics. 2012;129:e1446–52.
   PubMed Web of Science ®Google Scholar
• Bugenske E, Stokley S, Kennedy A, et al. Middle school vaccination requirements and adolescent vaccination coverage. Pediatrics. 2012;129:1056–1063.
   PubMed Web of Science ®Google Scholar
• Annual HPV vaccine coverage 2013 to 2014: by PCT, local authority and area team - Publications - GOV.UK. [ cited 2015 May 17]. Available from: https://www.gov.uk/government/statistics/annual-hpv-vaccine-coverage-2013-to-2014-by-pct-local-authority-and-area-team.
   Google Scholar
• Wang X, Shutt KA, Vuong JT, et al. Changes in the population structure of invasive Neisseria meningitidis in the United States after quadrivalent meningococcal conjugate vaccine licensure. J Infect Dis. 2015;211:1887–1894.
   PubMed Web of Science ®Google Scholar
• Bijlsma MW, Bekker V, Brouwer MC, et al Epidemiology of invasive meningococcal disease in the Netherlands, 1960–2012: an analysis of national surveillance data. Lancet Infect Dis. 2014;14:805–812.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Ramsay ME, Gray S, et al. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis. 2006;6:616–617. author reply 617–8
   PubMed Web of Science ®Google Scholar